Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis to Webcast Investor & Analyst Day 2016

GlobeNewswire June 27, 2016

Biotechnology Stocks on our Radar -- Array BioPharma, PDL BioPharma, Advaxis, and TetraLogic Pharma

PR Newswire June 16, 2016

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer

GlobeNewswire June 8, 2016

Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports

GlobeNewswire June 6, 2016

Advaxis to Host Investor & Analyst Day on June 28, 2016

GlobeNewswire May 17, 2016

UPDATE – Advaxis to Present at Jefferies 2016 Healthcare Conference

GlobeNewswire May 5, 2016

Advaxis to Present at Jeffries 2016 Healthcare Conference

GlobeNewswire May 5, 2016

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma

GlobeNewswire April 28, 2016

Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting

GlobeNewswire April 25, 2016

AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform

GlobeNewswire April 19, 2016

Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company's Lm Technology(TM) Platform

GlobeNewswire April 18, 2016

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform

GlobeNewswire April 13, 2016

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts

GlobeNewswire April 5, 2016

Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit

GlobeNewswire April 4, 2016

Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort

GlobeNewswire March 29, 2016

UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

GlobeNewswire March 23, 2016

Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

GlobeNewswire March 23, 2016

Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research

GlobeNewswire March 21, 2016

Advaxis to Present at Barclays Global Healthcare Conference

GlobeNewswire March 14, 2016

Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors

GlobeNewswire March 11, 2016